Le Lézard

News by subject: TRI

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

13 january 2025

09:00
Since the COVID-19 pandemic, mRNA vaccines have been recognized as the most important platform for infectious disease prevention and continue to be utilized across various fields. However,...

09:00
WAT Medical Enterprise collaborated with Concordia University and Mitacs Canada to conduct a study using ObeEnd, the neuromodulation device designed by WAT for weight and health management. The study revealed that electroacupuncture may help improve...

08:31
AbbVie and REGENXBIO Inc. today announced updates to the ABBV-RGX-314 clinical program. ABBV-RGX-314 in Wet...

08:30
Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast...

08:01
Ginkgo Bioworks , which is building the leading platform for cell programming and biosecurity, today announced a research collaboration with Universal Cells, an Astellas company, to optimize next-generation induced pluripotent stem cell...

08:00
Phase 1 interim results expected for SPY002, two distinct extended half-life TL1A antibodies, in 2Q2025 Phase 1 interim results expected for SPY003, an extended half-life IL-23 antibody, in 2H2025 Phase 2 platform trial in ulcerative colitis (UC)...

08:00
Akebia...

07:30
-- Initiated dosing in Phase 1 clinical trial cohort evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction (GEJ) cancer -- -- Expect to report initial data from...

07:05
Sling Therapeutics, Inc., a late-stage biopharmaceutical company focused on the development of an oral small molecule for the treatment of thyroid eye disease (TED), will announce topline data from the Phase 2b/3 LIDS trial of linsitinib in patients...

07:00
? Launched Revuforj® (revumenib) for treatment of R/R acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older ? ? Revumenib added to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)for AML and ALL...

06:30
Strategy prioritizes most accelerated path to first potential approval  Initial NDA submission expected by mid-year for zidesamtinib in TKI pre-treated ROS1-positive NSCLC population, with topline pivotal data anticipated in the first half of 2025...

01:00
The VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay is the first clinically approved in-situ hybridisation (ISH) test with the sensitivity to assess the full spectrum of B-cell lymphoma subtypes.1,2 The test helps differentiate a B-cell...


12 january 2025

16:00
-- Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT® (avapritinib) launch and evolving SM prevalence estimates --  -- Expect to achieve $2 billion in AYVAKIT revenue by 2030 -- -- BLU-808...

12:00
IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 43rd Annual J.P. Morgan Healthcare Conference and provided 2025 corporate...


10 january 2025

19:59
Canary Cure Therapeutics, a pioneer in next-generation RNA therapeutics development, today announced breakthrough preclinical results for its lead candidate CCT-217, addressing two critical challenges in current obesity treatments: muscle mass loss...

17:55
Expert Systems, a hybrid AI enabled drug discovery and development accelerator, announced a significant milestone in a development of Traws Pharma, Inc. 's H5N1 antiviral program. The investigational drug, Tivoxavir Marboxil, has shown encouraging...

15:20
A new study in JAMA Internal Medicine confirms acupuncture's effectiveness in relieving chronic sciatica caused by herniated discs. The trial showed significant pain reduction and improved functionality, with benefits lasting up to a year. Acubalance...

12:59
Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies that utilize first-in-class, checkpoint modifiers, today announced that its Phase 1b clinical trial, evaluating VRON-0200 for HBV...

12:30
Regor Therapeutics Group ("Regor"), a privately-held clinical-stage global biopharmaceutical...

12:00
MimiVax, Inc. and UI Pharmaceuticals are proud to announce the successful clinical manufacture of SurVaxM, a novel immunotherapeutic vaccine targeting Glioblastoma (GBM), at UIP's...

10:39
This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidly into the...

08:18
OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. anaphylaxis) and is based on the proprietary AmorphOX® technology.The clinical study, OX640-002, evaluated both pharmacokinetic and...

08:05
MetaVia Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it is holding an Advisory Committee meeting today, at the 9th Annual MASH-TAG 2025 Conference, to discuss the previously...

08:00
Johnson &...

08:00
Verismo Therapeutics, a clinical-stage CAR T company developing novel KIR-CAR platform technology, today announced that it has dosed the first patient in its CELESTIAL-301 Phase 1 clinical trial. The patient was infused at Sarah Cannon Research...

08:00
The US FDA, Health Canada, European Medicines Authority, and the Australian Therapeutic Goods Administration authorized the Company's global, randomized Phase 3 study (INVINCIBLE-3) in Metastatic Soft Tissue SarcomaTwenty-three sites are currently...

08:00
Tyra Biosciences, Inc. , a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that the U.S. Food and Drug...

08:00
Diakonos Oncology, a clinical-stage biotechnology company leveraging proprietary dendritic cell technology to address critical and unmet therapeutic needs in late-stage and aggressive cancers, announced that it will present its latest developments at...

08:00
--ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million-- --2025 Global ARIKAYCE Revenues Expected to be Between $405 Million and...

07:52
Immorta Bio Inc., a leader in longevity-focused biotechnologies, announced today that it will present its latest developments at the upcoming Biotech Showcase in San Francisco, CA. The company's presentation will provide insights into its...

07:49
Cmbio®, a global leader in multi-omics science and digital biology, is pleased to announce the purchase of the e[datascientist]tm software platform through an Asset Sale Agreement with CBW Recovery LLP and Eagle Genomics Limited (In Administration)....

07:00
Nektar Therapeutics today announced the company has completed target enrollment in its REZOLVE-AD Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis....

07:00
Mediar Therapeutics, Inc., a clinical stage biotechnology company advancing a portfolio of first-in-class therapies designed to halt fibrosis progression, announced a global licensing agreement with Eli Lilly and Company to advance MTX-463 into a...

04:00
JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the Center for Drug Evaluation (CDE) of the National Medical...

01:40
SN BioScience today announced that its lead asset SNB-101 has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a Phase 1b/2 clinical trial. This achievement follows the designation of SNB-101 as...


9 january 2025

16:30
Servier today announced updates to two of its Phase 3 programs evaluating TIBSOVO (ivosidenib tablets) in isocitrate dehydrogenase 1 (IDH1)-mutated cancers. The first patient has been...

13:57
Partner Therapeutics, Inc. (PTx) today announced a collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and...

12:30
Children's Brain Tumor Network (CBTN) welcomes Intermountain Primary Children's Hospital as a new member institution. The CBTN principal investigators are Dr. Samuel Cheshier, pediatric neurosurgeon, and Dr. Nicholas Whipple, pediatric...

10:34
Kindeva Drug Delivery, a global CDMO and drug delivery expert, and Emervax, a developer of a proprietary circular RNA-based vaccine platform (emxRNATM), today announced an exclusive partnership to co-develop a game-changing solution for the...

09:26
Argon Medical Devices, a leading provider of device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology procedures, announced the first patient enrollment in the CLEAN-PE study. The prospective,...

09:15
Dr Jose-Carlos Gutiérrez-Ramos is the Chief Science Officer at Danaher Corporation. He has held senior drug discovery roles at Pfizer, Abbvie, and GSK. As CEO and President of Synlogic, he led the company from early drug discovery to clinical stage...

08:39
Applying a newly identified biophysical mechanism of enzyme activation, researchers at the longevity therapeutics division of the diversified biopharmaceutical company CCM Biosciences, Inc., have discovered and characterized first-in-class enzyme...

08:17
Biofidelity, a leader in innovative genomic solutions, and CellCarta, the global contract research organization (CRO) partner of choice for biopharmaceutical companies seeking precision medicine solutions, today announced a strategic partnership...

08:05
Today, Dr. Jim Wilson, President and CEO of GEMMA Biotherapeutics ("GEMMABio") and co-founder of iECURE commented on the company's announcement of preliminary findings of complete clinical response for the first infant to receive treatment for...

08:04
Sen-Jam Pharmaceutical, a leader in innovative anti-inflammatory care, today announced the submission of a new patent application that introduces a novel composition and method to target obesity and metabolic disorders. The patent focuses on...

08:04
INOVIO , a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today highlighted anticipated milestones for 2025 and key...

08:04
Johnson & Johnson today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S Food and Drug Administration (FDA) for the treatment of...

08:00
Today, Astellas Pharma Canada Inc. is proud to announce that Health Canada...

08:00
Boehringer Ingelheim and Synaffix B.V. ("Synaffix"), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of best-in-class antibody-drug conjugates (ADCs), today announced that Boehringer...

07:58
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced a significant milestone for its proprietary Nectin-4 targeted ADC (9MW2821). On January 8, 2025, 9MW2821 was granted Breakthrough Therapy Designation...

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16